logo
Plus   Neg
Share
Email

Stock Alert: NGM Biopharma Up 24% After Liver Disease Drug Trial Meets Endpoints

Shares of NGM Biopharmaceuticals Inc. (NGM) is gaining nearly 24% on after the pharma company said its liver disease drug's stage-2 study achieved positive results.

Phase 2 study of Aldafermin, NGM's lead drug candidate developed as a once-daily treatment for patients with non-alcoholic steatohepatitis. The drug compared to placebo achieved significant change in absolute liver fat content.

NGM Biopharmaceuticals operates as a clinical-stage biopharmaceutical company. The company focuses on developing novel therapeutics based on scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic, and ophthalmic diseases.

NGM is currently trading at $20.00, up $3.81 or 23.53%, on the NYSE, on a volume of 1.4 million shares, above its three-month average volume of 256 thousand.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Microsoft is in agreement with Alaska Airlines to enable flying more sustainably on three most popular routes traveled by Microsoft employees on Alaska Airlines, which uses sustainable aviation fuel (SAF). The SAF, supplied by SkyNRG, is an important option for the aviation industry to reduce carbon (CO2) emissions on a life-cycle basis. Walmart and Sam's Club announced options for customers to safely dispose unused, unwanted and expired medication throughout the year. With this, the retail giant aims to help the public from potential danger for misuse and abuse of prescription medications. On Saturday, October 24, the company will host in-person medication disposal events at select store and club locations across U.S. Telecom giant AT&T, Inc. reported Thursday a 24 percent decline in profit for the third quarter, primarily hurt by lower revenues across all its operating segments amid the impact from COVID-19 pandemic. Adjusted earnings for the quarter met analysts' expectations, while quarterly revenues topped their estimates.
Follow RTT